Literature DB >> 20560139

Function of OPG as a traffic regulator for RANKL is crucial for controlled osteoclastogenesis.

Shigeki Aoki1, Masashi Honma, Yoshiaki Kariya, Yuko Nakamichi, Tadashi Ninomiya, Naoyuki Takahashi, Nobuyuki Udagawa, Hiroshi Suzuki.   

Abstract

The amount of the receptor activator of NF-κB ligand (RANKL) on the osteoblastic cell surface is considered to determine the magnitude of the signal input to osteoclast precursors and the degree of osteoclastogenesis. Previously, we have shown that RANKL is localized predominantly in lysosomal organelles, but little is found on the osteoblastic cell surface, and consequently, the regulated subcellular trafficking of RANKL in osteoblastic cells is important for controlled osteoclastogenesis. Here we have examined the involvement of osteoprotegerin (OPG), which is currently recognized as a decoy receptor for RANKL, in the regulation of RANKL behavior. It was suggested that OPG already makes a complex with RANKL in the Golgi apparatus and that the complex formation is necessary for RANKL sorting to the secretory lysosomes. It was also shown that each structural domain of OPG is indispensable for exerting OPG function as a traffic regulator. In particular, the latter domains of OPG, whose physiologic functions have been unclear, were indicated to sort RANKL molecules to lysosomes from the Golgi apparatus. In addition, the overexpression of RANK-OPG chimeric protein, which retained OPG function as a decoy receptor but lost the function as a traffic regulator, inhibited endogenous OPG function as a traffic regulator selectively in osteoblastic cells and resulted in the upregulation of osteoclastogenic ability despite the increased number of decoy receptor molecules. Conclusively, OPG function as a traffic regulator for RANKL is crucial for regulating osteoclastogenesis at least as well as that as a decoy receptor.
© 2010 American Society for Bone and Mineral Research.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20560139     DOI: 10.1002/jbmr.89

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  12 in total

Review 1.  Mechanisms of RANKL delivery to the osteoclast precursor cell surface.

Authors:  Masashi Honma; Yuki Ikebuchi; Hiroshi Suzuki
Journal:  J Bone Miner Metab       Date:  2020-10-12       Impact factor: 2.626

2.  Role of DNA methylation in the regulation of the RANKL-OPG system in human bone.

Authors:  Jesús Delgado-Calle; Carolina Sañudo; Agustín F Fernández; Raúl García-Renedo; Mario F Fraga; José A Riancho
Journal:  Epigenetics       Date:  2012-01-01       Impact factor: 4.528

Review 3.  The Osteocyte: New Insights.

Authors:  Alexander G Robling; Lynda F Bonewald
Journal:  Annu Rev Physiol       Date:  2020-02-10       Impact factor: 19.318

Review 4.  Regulatory mechanisms of RANKL presentation to osteoclast precursors.

Authors:  Masashi Honma; Yuki Ikebuchi; Yoshiaki Kariya; Hiroshi Suzuki
Journal:  Curr Osteoporos Rep       Date:  2014-03       Impact factor: 5.096

Review 5.  Bisphophonates in CKD patients with low bone mineral density.

Authors:  Wen-Chih Liu; Jen-Fen Yen; Cheng-Lin Lang; Ming-Tso Yan; Kuo-Cheng Lu
Journal:  ScientificWorldJournal       Date:  2013-12-31

6.  Treatment of OPG-deficient mice with WP9QY, a RANKL-binding peptide, recovers alveolar bone loss by suppressing osteoclastogenesis and enhancing osteoblastogenesis.

Authors:  Yuki Ozaki; Masanori Koide; Yuriko Furuya; Tadashi Ninomiya; Hisataka Yasuda; Midori Nakamura; Yasuhiro Kobayashi; Naoyuki Takahashi; Nobuo Yoshinari; Nobuyuki Udagawa
Journal:  PLoS One       Date:  2017-09-22       Impact factor: 3.240

7.  Do epigenetic marks govern bone mass and homeostasis?

Authors:  Jesús Delgado-Calle; Pablo Garmilla; José A Riancho
Journal:  Curr Genomics       Date:  2012-05       Impact factor: 2.236

8.  Tartrate-resistant acid phosphatase (TRAP) co-localizes with receptor activator of NF-KB ligand (RANKL) and osteoprotegerin (OPG) in lysosomal-associated membrane protein 1 (LAMP1)-positive vesicles in rat osteoblasts and osteocytes.

Authors:  L B Solberg; E Stang; S-H Brorson; G Andersson; F P Reinholt
Journal:  Histochem Cell Biol       Date:  2014-09-09       Impact factor: 4.304

9.  Peptide drugs accelerate BMP-2-induced calvarial bone regeneration and stimulate osteoblast differentiation through mTORC1 signaling.

Authors:  Yasutaka Sugamori; Setsuko Mise-Omata; Chizuko Maeda; Shigeki Aoki; Yasuhiko Tabata; Ramachandran Murali; Hisataka Yasuda; Nobuyuki Udagawa; Hiroshi Suzuki; Masashi Honma; Kazuhiro Aoki
Journal:  Bioessays       Date:  2016-06-27       Impact factor: 4.345

10.  LAPTM5 is transactivated by RUNX2 and involved in RANKL trafficking in osteoblastic cells.

Authors:  Yuan-Ming Geng; Cheng-Xia Liu; Wei-Ying Lu; Ping Liu; Pei-Yan Yuan; Wei-Long Liu; Ping-Ping Xu; Xiao-Qing Shen
Journal:  Mol Med Rep       Date:  2019-09-16       Impact factor: 2.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.